RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
葡萄膜黑色素瘤：从分子生物学到新型免疫治疗与纳米医学
英文原题：From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma.
查看英文原题
From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
葡萄膜黑色素瘤的分子生物学研究促成了新型免疫治疗方法的开发，包括tebentafusp——一种T细胞重定向双特异性融合蛋白。目前正在研究更多生物标志物。因此，联合免疫治疗以及双功能检查点抑制性T细胞衔接器和NK 细胞的免疫治疗正在开发中。当前试验涵盖TIL（肿瘤浸润淋巴细胞）、IKKb成熟树突状细胞疫苗，或负载自体肿瘤RNA的自体树突状细胞。另一种治疗UM的潜在方法可能基于T细胞受体工程而非抗体修饰。针对癌症的免疫动员单克隆T细胞受体（TCR），称为ImmTAC TM分子，代表了这样一种方法。此外，纳米医学，尤其是miRNA方法，在未来的试验中具有前景。最后，能够用同一分子实现诊断和治疗的诊疗一体化放射性药物为这项研究带来了希望。
展开英文摘要原文
Molecular biology studies of uveal melanoma have resulted in the development of novel immunotherapy approaches including tebentafusp-a T cell-redirecting bispecific fusion protein. More biomarkers are currently being studied. As a result, combined immunotherapy is being developed as well as immunotherapy with bifunctional checkpoint inhibitory T cell engagers and natural killer cells.
Current trials cover tumor-infiltrating lymphocytes (TIL), vaccination with IKKb-matured dendritic cells, or autologous dendritic cells loaded with autologous tumor RNA. Another potential approach to treat UM could be based on T cell receptor engineering rather than antibody modification. Immune-mobilizing monoclonal T cell receptors (TCR) against cancer, called ImmTAC TM molecules, represent such an approach.
Moreover, nanomedicine, especially miRNA approaches, are promising for future trials.
Finally, theranostic radiopharmaceuticals enabling diagnosis and therapy with the same molecule bring hope to this research.
论文信息
- 作者
- Synoradzki KJ、Paduszyńska N、Solnik M、Toro MD、Bilmin K、Bylina E、Rutkowski P、Yousef YA
- 第一作者单位
- Environmental Laboratory of Pharmacological and Toxicological Research, Mossakowski Medical Research Institute, Polish Academy of Sciences, 5 Pawinskiego Str., 02-106 Warsaw, Poland.Poland
- 通讯作者单位
- Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 5 Roentgen Str., 02-781 Warsaw, Poland.Poland
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Current oncology (Toronto, Ont.)2024 Feb 1
- 原文标识
- PubMed 38392052 · DOI 10.3390/curroncol31020058
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →